Heeg E, van de Mheen PJM, Maaren MCV, et al. - All triple-negative breast cancer (TNBC) individuals diagnosed between 2006 and 2014 who received adjuvant chemotherapy in the Netherlands were recognized in order to ascertain whether time to chemotherapy (TTC) beyond 30 days was related to decreased 10-year overall survival in TNBC individuals. In matched individuals who underwent breast-conserving surgery (BCS) (n = 904), for people with TTC within 30 days, 10-year overall survival was favorable. Compared with those with TTC within 30 days, people with TTC beyond 30 days were more prone to die within 10 years following surgery. In matched controls who underwent mastectomy (n = 1568), no variation in 10-years overall survival between those with TTC within or beyond 30 days, nor a heightened risk of death for those with TTC beyond 30 days was noted. In conclusion, in TNBC individuals who underwent BCS, the beginning of adjuvant chemotherapy beyond 30 days was related to reduced 10-years overall survival. Hence, the timelier beginning of chemotherapy in TNBC cases undergoing BCS appears assured.